User Tools

Site Tools


2005

2005

Since 2005, state-of-the-art therapy in glioblastoma multiforme consists of maximal safe resection followed by combined radiotherapy and chemotherapy with temozolomide, according to Stupp regimen 1). 2) , particularly in patients that demonstrate MGMT promoter methylation. At recurrence there is no consensus as to the standard of care as no therapeutic options have produced substantial survival benefit 3).


Juha Hernesniemi, published the lateral supraorbital craniotomy 4) it avoids the approach through the sylvian fissure (SF) and irrespective of the SF anatomy approaches the aneurysms immediately subfrontally. The SF is only partially open.


The H index was suggested in 2005 by Jorge E. Hirsch, a physicist at UCSD, as a tool for determining theoretical physicists' relative quality and is sometimes called the Hirsch index or Hirsch number.


Since its introduction in 1991, the Marshall CT classification has become largely accepted for its descriptive and predictive value. For example, the IMPACT (International Mission for Prognosis and Analysis of Clinical Trial in TBI) prognostic model applies the Marshall CT score for 6-month outcome prediction in patients with moderate to severe TBI 5).

The Marshall CT classification was, however, not designed for outcome prediction, and in 2005, Maas et al redesigned it for 6-month mortality prediction, resulting in the Rotterdam CT score 6).


WANS is a non-profit public benefit association and is established in October 2005 as an honor society to promote cooperation and camaraderie amongst world leaders of neurosurgery, exchange of scientific knowledge and recognition of major contributors to the specialty.

1)
Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–1382.
2)
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. PubMed PMID: 15758009.
3)
Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol. 2013 Jan;15(1):4-27. doi: 10.1093/neuonc/nos273. Epub 2012 Nov 7. Review. PubMed PMID: 23136223; PubMed Central PMCID: PMC3534423.
4)
Hernesniemi J, Ishii K, Niemelä M, Smrcka M, Kivipelto L, Fujiki M, Shen H. Lateral supraorbital approach as an alternative to the classical pterional approach. Acta Neurochir Suppl. 2005;94:17-21. PubMed PMID: 16060236.
5)
Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med. 2008;5 (8):e165.
6)
Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic character- istics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. Neurosurgery. 2005;57 (6):1173-1182; discussion 1173-1182.
2005.txt · Last modified: 2018/11/26 09:34 by administrador